98%
921
2 minutes
20
Objective: To assess the varying myopia control outcomes between morning (QM) and evening (QN) application of 0.01% atropine drops in conjunction with orthokeratology (ortho-K) therapy in myopic children.
Methods: A total of 163 right eyes of myopic children were included, receiving either morning or evening 0.01% atropine combined with ortho-K, with 78 in the QM group. Age, gender, spherical equivalent refraction, axial length, e-value, average K-reading (Ave-K), and pupil diameter (PD) were all documented as baseline characteristics. Follow-up assessments at 1-, 3-, 6-, 9-, and 12-month visits were centered on alterations in treatment zone diameter (TZD), decentration, PD, and axial elongation. Parental refraction and children's behavioral factors, such as daily near-work time, outdoor activity time, reading and writing posture, and sweets consumption, were gathered through a questionnaire.
Results: At baseline, there were no significant differences in ocular characteristics between the two groups. After one month, the QM group exhibited a significantly larger PD compared to the QN group (4.09 ± 0.67 mm vs. 3.84 ± 0.76 mm, P = 0.03), while measurements for TZD and decentration showed no significant variance. Over the course of 1 year, the QM group demonstrated significantly less axial elongation than the QN group (0.13 ± 0.19 mm vs. 0.21 ± 0.16 mm, P < 0.05). Parental refraction and behavioral factors were similar between the groups, except for a lower consumption of sweets in the QM group. Regression analysis revealed that the timing of atropine administration, age, PD, and reading and writing posture were significant predictors of axial elongation over the 12-month period.
Conclusion: Morning administration of 0.01% atropine eye drops combined with ortho-K shows greater efficacy in managing axial elongation than evening administration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416594 | PMC |
http://dx.doi.org/10.4103/IJO.IJO_3107_24 | DOI Listing |
Vestn Oftalmol
September 2025
Azerbaijan Medical University, Baku, Azerbaijan.
Objective: This study evaluated changes in ocular parameters in patients with progressive myopia receiving 0.01% atropine.
Material And Methods: The study included 35 children (18 girls, 51.
J Inflamm Res
September 2025
Department of Optometry, School of Health and Welfare, Dongshin University, Naju, Korea.
Objective: To evaluate the therapeutic efficacy and inflammatory modulatory effects of combined 0.01% atropine eye drops and orthokeratology (OK) lenses in controlling myopia progression among adolescent patients.
Methods: This retrospective study analyzed clinical data from 90 adolescent patients (90 eyes) with myopia treated from April 2021 to June 2023.
Am J Cardiol
September 2025
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. Electronic address:
Introduction: A myocardial bridge (MB) is a condition where a segment of an epicardial coronary artery passes through the myocardial muscle. While traditionally regarded as benign, MBs have been associated with various cardiovascular conditions. Therefore, assessing their hemodynamic impact is crucial for informed treatment decisions.
View Article and Find Full Text PDFJ Optom
August 2025
Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University, 18 Zetian Road, Futian District, Shenzhen, 518040, China. Electronic address:
Purpose: To evaluate the efficacy of weekly unilateral application of 1 % atropine on reducing anisometropia in Chinese children with low myopia.
Methods: In this retrospective cohort study, anisometropic children aged 6-12 years receiving atropine in the more myopic eye for at least 3 months were included in atropine group (n = 150), and baseline matched counterparts without atropine use were included in control group (n = 50). Changes in spherical equivalent refraction (SER), axial length (AL) and other biometric parameters between each visits were analyzed.
In Vivo
August 2025
Nobel Eye Institute, Taipei, Taiwan, R.O.C.;
Background/aim: This study investigated the efficiency of combined atropine (ATR) and defocus incorporated multiple segments' (DIMS) spectacle lens ATR monotherapy in controlling high myopia in children.
Patients And Methods: A retrospective cohort study was performed, enrolling patients treated with either ATR monotherapy (n=35 eyes) or a combination of ATR and DIMS lenses (n=32 eyes). The primary outcomes were the spherical equivalent refraction (SER) progression and axial length (AXL) elongation, and were measured over a one year follow up period.